Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
暂无分享,去创建一个
John D. Roberts | L. Haugh | R. Branda | R. Albertini | J. Stewart | J. Belinson | J. Roberts | B. Grant | J. Dorighi | A. L. Moore
[1] W. Urba,et al. Intraperitoneal lymphokine-activated killer cell/interleukin-2 therapy in patients with intra-abdominal cancer: immunologic considerations. , 1989, Journal of the National Cancer Institute.
[2] L. Moretta,et al. Phenotypic and functional characteristics of tumor‐associated lymphocytes in patients with malignant ascites receiving intraperitoneal infusions of recombinant interleukin‐2 (ril‐2) , 1989, International journal of cancer.
[3] D. Longo,et al. Human natural lymphocyte effector cells: definition, analysis of activity, and clinical effectiveness. , 1988, Journal of the National Cancer Institute.
[4] R. Albertini,et al. Effect of commercial peritoneal dialysis fluids on the lytic function of lymphokine-activated killer cells. , 1988, Journal of biological response modifiers.
[5] T. Whiteside,et al. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells. , 1988, Cancer research.
[6] J. Yannelli,et al. The generation of human lymphokine-activated killer cells in various serum-free media. , 1988, Journal of immunological methods.
[7] J. Hank,et al. Status and potential of interleukin-2 for the treatment of neoplastic disease. , 1987, Oncology.
[8] W. M. Linehan,et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.
[9] S. Rosenberg,et al. Immunotherapy of intraperitoneal cancer with interleukin 2 and lymphokine-activated killer cells reduces tumor load and prolongs survival in murine models. , 1987, Cellular immunology.
[10] S. Rosenberg,et al. Intraperitoneal administration of interleukin-2 in patients with cancer. , 1986, Archives of surgery.
[11] S. Rosenberg,et al. Optimal methods for generating expanded lymphokine activated killer cells capable of reducing established murine tumors in vivo. , 1986, Journal of immunological methods.
[12] C. Balch,et al. Lysis of human solid tumor cells by lymphokine-activated natural killer cells. , 1986, Journal of immunology.
[13] E. Grimm,et al. The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral blood lymphocytes. , 1985, Cellular immunology.
[14] N. Hacker,et al. Intraperitoneal Recombinant α-Interferon for “Salvage” Immunotherapy in Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study , 1985 .
[15] S. Rosenberg,et al. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. , 1985, Journal of immunology.
[16] S. Rosenberg,et al. Lymphokine-activated killer cell phenomenon. Lysis of natural killer- resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes , 1982, The Journal of experimental medicine.
[17] E. Fenig,et al. A pilot study of intraperitoneal recombinant interleukin-2 and ex vivo activated intracavitary lymphocytes in patients with malignant peritoneal spread: I. Clinical aspects. , 1989, Molecular biotherapy.
[18] E. Grimm,et al. Current understanding of the lymphokine-activated killer cell phenomenon. , 1988, Progress in experimental tumor research.
[19] J. Rossio,et al. The BRMP IL-2 reference reagent. , 1986, Lymphokine research.
[20] V. Devita,et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. , 1978, Cancer treatment reports.